Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.46 |
| ▸ | CCR9 | P51686 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3259497 | 0.93 | MEN1 (0.55) | MEN1KMT2AROCK1TRPV1RAB9A | |
| SCHEMBL3259326 | 0.89 | MEN1 (0.53) | MEN1KMT2ATRPV1CCR9RAB9A | |
| SCHEMBL6364550 | 0.82 | MEN1 (0.63) | MEN1KMT2AROCK1TRPV1RAB9A | |
| SCHEMBL3158017 | 0.77 | MAOB (0.47) | MEN1KMT2AROCK1PTGDR2CCR2 | |
| SCHEMBL6358712 | 0.77 | MEN1 (0.61) | MEN1KMT2ATRPV1RAB9ANPC1 | |
| SCHEMBL2810002 | 0.75 | KDM4E (0.51) | MEN1KMT2ATRPV1HDAC6CYP1A2 | |
| SCHEMBL3879676 | 0.75 | GRM4 (0.64) | MEN1KMT2AROCK1TRPV1RAB9A | |
| Hydrochloric Acid SCHEMBL2811025 | 0.74 | KDM4E (0.50) | MEN1KMT2ATRPV1CYP1A2CYP2C19 | |
| SCHEMBL3890282 | 0.73 | MEN1 (1.00) | MEN1KMT2ATRPV1RAB9ANPC1 | |
| SCHEMBL3880418 | 0.73 | MEN1 (0.56) | MEN1KMT2ATRPV1RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407950-B2 | N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands | SANOFI-AVENTIS (FR) | 2008-08-05 | — | — | US | claimed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | claimed |
| EP-1841737-B1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI AVENTIS (FR) | 2010-03-10 | — | — | EP | disclosed |
| US-7557134-B2 | N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands | SANOFI-AVENTIS (FR) | 2009-07-07 | — | — | US | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-7544803-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-06-09 | — | — | US | disclosed |
| US-20080255131-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2008-10-16 | — | — | US | disclosed |
| US-7407950-B2 | N-(heteroaryl)-1H-indole-2-carboxamide derivatives and their use as vanilloid TRPV1 receptor ligands | SANOFI-AVENTIS (FR) | 2008-08-05 | — | — | US | disclosed |
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | SANOFI-AVENTIS (FR) | 2007-11-08 | — | — | US | disclosed |
| EP-1841737-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | Sanofi-Aventis (FR) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006072736-A1 | N- (HETEROARYL) -1H-INDOLE-2-CARB0XAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | SANOFI-AVENTIS (FR) | 2006-07-13 | — | — | WO | disclosed |
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165049-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | MEN1 3499/4885KMT2A 3902/4885ROCK1 1473/4885 |
| US-20070259946-A1 | N-(isoquinol-5-yl)-5-fluoro-1-[((3-trifluoromethyl)phenyl)methyl]-1H-indole-2-carboxamide; transient receptor potential vanilloid (capsaicin receptor) antagonist or agonist; analgesic, antiallergen agent; pain and irritation of the skin, eyes and mucous membrane | TRPV1, TRPV5, TRPA1 | MEN1 4713/4885KMT2A 1863/4885ROCK1 2604/4885 |
| US-20080255131-A1 | N-(HETEROARYL)-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES AND THEIR USE AS VANILLOID TRPV1 RECEPTOR LIGANDS | TRPV1, TRPV3, TRPV2 | MEN1 4692/4885KMT2A 3063/4885ROCK1 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.